Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
CYP1B1-IN-1
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "CYP1B1-IN-1" in MCE Product Catalog:
Cat. No.: HY-150557
CAS No.: 842122-33-2
Target:
Research Areas:
CYP1B1-IN-1 (Compound 9e) is a selective cytochrome P450 1B1 (CYP1B1) inhibitor with an IC50 of 0.49 nM .
1
1 Cited Publications
Target:
Research Areas:
PROTAC CYP1B1 degrader-1 is a CYP1B1 PROTAC degrader with a human IC50 of 95.1 nM. PROTAC CYP1B1 degrader-1 induces concentration-dependent CYP1B1 degradation. PROTAC CYP1B1 degrader-1 can be used for the research of CYP1B1-mediated Docetaxel (HY-B0011)-resistant prostate cancer .
Target:
Research Areas:
CYP1B1-IN-7 (compound 2a) is a selective inhibitor of CYP1B1 (IC50: 75 nM). CYP1B1-IN-7 also reverses resistance (IC50: 29 μM) and exhibits cytotoxicity in the CYP1B1-overexpressing MCF-7 cell line that is resistant to Docetaxel (HY-B0011) .
Cat. No.: HY-W472509
CAS No.: 73804-65-6
Synonyms: 11-Hydroxy-5,8,12,14-eicosatetraenoic acid
Target:
Research Areas:
11-HETE (11-Hydroxy-5,8,12,14-eicosatetraenoic acid) is the activator for cytochrome P450. 11-HETE upregulates the mRNA expressions of CYP1B1, CYP1A1, CYP4A11, CYP4F11, and CYP4F2, induces cell hypertrophy in RL-14 cell, and exhibits potential to be used in cardiovascular diseases .
Cat. No.: HY-152079
CAS No.: 2872575-51-2
Target:
Research Areas:
CYP1B1-IN-3 is a potent and selective CYP1B1 inhibitor with IC50 values of 6.6, 347.3, >10000 nM for CYP1B1, CYP1A1, CYP1A2, respectively. CYP1B1-IN-3 inhibits cell migration and invasion. CYP1B1-IN-3 inhibits P-gp, AKT/ERK, FAK/SRC, and EMT pathways .
Cat. No.: HY-174425
CAS No.: 3077254-39-5
Target:
Research Areas:
CYP1B1-IN-9 is a highly selective and competitive CYP1B1 Inhibitor with IC50 values of 1.48 nM, > 100 μM, and > 80 μM for CYP1B1, CYP1A1, and CYP1A2, respectively. CYP1B1-IN-9 significantly inhibits the migration and invasion of A549/T cells. CYP1B1-IN-9 has the ability to resensitize Paclitaxel (HY-B0015)-resistant cells, and good metabolic stability and safety, and shows favorable pharmacokinetic parameters. CYP1B1-IN-9 can be used for the study of tumor-drug resistance .
Cat. No.: HY-187206
Target:
Research Areas:
CYP1B1-IN-15 is a CYP1B1 inhibitor with an IC50 of 1.47 nM, and it exhibits high selectivity against six major CYP subtypes. CYP1B1-IN-15 exerts competitive inhibitory effects by competing with substrates for binding to the active site of CYP1B1. CYP1B1-IN-15 enhances the inhibitory effect of Paclitaxel (HY-B0015) on the proliferation of paclitaxel-resistant cancer cells, and inhibits the migration and invasion of paclitaxel-resistant cancer cells. CYP1B1-IN-15 can be used in studies related to paclitaxel-resistant non-small cell lung cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
